Show simple item record

dc.contributor.authorFrijhoff, J
dc.contributor.authorWinyard, PG
dc.contributor.authorZarkovic, N
dc.contributor.authorDavies, SS
dc.contributor.authorStocker, R
dc.contributor.authorCheng, D
dc.contributor.authorKnight, AR
dc.contributor.authorTaylor, EL
dc.contributor.authorOettrich, J
dc.contributor.authorRuskovska, T
dc.contributor.authorGasparovic, AC
dc.contributor.authorCuadrado, A
dc.contributor.authorWeber, D
dc.contributor.authorPoulsen, HE
dc.contributor.authorGrune, T
dc.contributor.authorSchmidt, HH
dc.contributor.authorGhezzi, P
dc.date.accessioned2016-06-21T15:32:52Z
dc.date.issued2015-11-19
dc.description.abstractSIGNIFICANCE: Oxidative stress is considered to be an important component of various diseases. A vast number of methods have been developed and used in virtually all diseases to measure the extent and nature of oxidative stress, ranging from oxidation of DNA to proteins, lipids, and free amino acids. RECENT ADVANCES: An increased understanding of the biology behind diseases and redox biology has led to more specific and sensitive tools to measure oxidative stress markers, which are very diverse and sometimes very low in abundance. CRITICAL ISSUES: The literature is very heterogeneous. It is often difficult to draw general conclusions on the significance of oxidative stress biomarkers, as only in a limited proportion of diseases have a range of different biomarkers been used, and different biomarkers have been used to study different diseases. In addition, biomarkers are often measured using nonspecific methods, while specific methodologies are often too sophisticated or laborious for routine clinical use. FUTURE DIRECTIONS: Several markers of oxidative stress still represent a viable biomarker opportunity for clinical use. However, positive findings with currently used biomarkers still need to be validated in larger sample sizes and compared with current clinical standards to establish them as clinical diagnostics. It is important to realize that oxidative stress is a nuanced phenomenon that is difficult to characterize, and one biomarker is not necessarily better than others. The vast diversity in oxidative stress between diseases and conditions has to be taken into account when selecting the most appropriate biomarker.en_GB
dc.description.sponsorshipThe authors acknowledge financial support from the European Cooperation in Science and Technology (COST Action BM1203/EU-ROS) (P.G.W., N.Z., T.R., A.C., H.E.P., H.H.H.W.S., P.G.), the Peptide Research Network of Excellence, European Cross-border Cooperation Programme INTERREG IV A France (Channel)-England, ERDF (P.G.), the Toyota foundation, Denmark (H.E.P.), a Senior Principal Research Fellowship from the National Health and Medical Research Council and National Health and Medical Research Council Project Grants 1020776 and 1060804 (R.S.), and National Institutes of Health Grant HL116263 (S.S.D.). A.K. is supported by a grant from the Defence Science and Technology Laboratory, United Kingdom, to P.G.W. and E.L.T.en_GB
dc.identifier.citationAntioxidants and Redox Signaling, 2015, Vol. 23, Issue 14, pp. 1144 - 1170en_GB
dc.identifier.doi10.1089/ars.2015.6317
dc.identifier.urihttp://hdl.handle.net/10871/22203
dc.language.isoenen_GB
dc.publisherMary Ann Lieberten_GB
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/26415143en_GB
dc.rightsThis is the final version of the article. Available from Mary Ann Liebert via the DOI in this record.en_GB
dc.titleClinical Relevance of Biomarkers of Oxidative Stress.en_GB
dc.typeArticleen_GB
dc.date.available2016-06-21T15:32:52Z
dc.identifier.issn1523-0864
exeter.place-of-publicationUnited States
dc.identifier.journalAntioxidants and Redox Signalingen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record